Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 22 (8), 2811-7

A New Class of Prolylcarboxypeptidase Inhibitors, Part 1: Discovery and Evaluation

Affiliations

A New Class of Prolylcarboxypeptidase Inhibitors, Part 1: Discovery and Evaluation

Thomas H Graham et al. Bioorg Med Chem Lett.

Abstract

A new structural class of potent prolylcarboxypeptidase (PrCP) inhibitors was discovered by high-throughput screening. The series possesses a tractable SAR profile with sub-nanomolar in vitro IC(50) values. Compared to prior inhibitors, the new series demonstrated minimal activity shifts in pure plasma and complete ex vivo plasma target engagement in mouse plasma at the 20 h post-dose time point (po). In addition, the in vivo level of CNS and non-CNS drug exposure was measured.

Similar articles

See all similar articles

Cited by 1 PubMed Central articles

  • Prolyl Carboxypeptidase and Its Inhibitors in Metabolism
    JK Jeong et al. Trends Endocrinol Metab 24 (2), 61-7. PMID 23245768.
    Proopiomelanocortin (POMC)-expressing neurons in the hypothalamus integrate a variety of central and peripheral metabolic inputs, and regulate energy homeostasis by contr …

LinkOut - more resources

Feedback